Novartis in Singapore continues to monitor the coronavirus (COVID-19) closely. Our focus is to ensure the health and safety of our people, the healthcare professionals we engage with daily, and to ensure the supply of our medicines to patients.
Currently, we do not anticipate any supply chain disruption. We expect that our existing stock is sufficient to cover production and distribution needs for the time being. We have solid processes in place to mitigate the risk of shortages, including safety stocks, dual sourcing and business continuity plans (as applicable).
As a global organisation, with over 108,000 people throughout the world, we are working very closely with our Swiss headquarters on our response. Accordingly, we have put the following additional measures in place:
We are continuously updating travel advisories in line with warning levels provided by the US Centers for Disease Control and Prevention and advice from the relevant local authorities.
We have issued guidance on how our people can protect themselves against the coronavirus infection by avoiding non-essential travel, practicing good personal hygiene and social distancing. We have also increased the frequency of cleaning and disinfection of surfaces at our sites. This is in line with local authority advice by the Ministry of Health.
We continue to offer flexible working options, split team arrangements and have encouraged our office based associates to work from home if they can do so. We also have various digital tools in place to allow our associates to work and collaborate virtually.
We are minimizing our face-to-face external meetings to protect the health of our communities, including healthcare professionals and the patients we serve. With exception to essential engagements that ensure continuity of supply of our medicines or care in a clinical trial setting, where no viable alternative to a face-to-face meeting is available.
We will continue to monitor the situation closely and adapt our measures as the situation evolves.
Novartis remains responsive to any developments regarding coronavirus and will take all necessary steps to protect our associates, healthcare professionals and patients as the situation evolves.